• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

Prof. Dr. rer. nat. Nils Blüthgen

Charité - Universitätsmedizin Berlin

Institute of Pathology
Campus Mitte
Chariteplatz 1
D 10117 Berlin

Humboldt Universität zu Berlin

Institut für Biologie
Campus Nord, Haus 18
Philippstr. 13
D 10115 Berlin

Tel: +49 (0)30 2093 92390
E-Mail: nils.bluethgen[at]charite.de



Scientific Scope

Our main research interest is to understand how molecular networks within cells such as signal transduction cascades or gene regulatory networks process information, how these networks are dysregulated in disease and how one can effectively interfere with these networks.  In our group, we develop and combine innovative methods from mathematical modeling, bioinformatics and quantitative biology as well as single cell analytics. One key research aim of the group is to understand how RAS-mediated oncogenic signaling pathways and its downstream gene regulatory networks mediate their oncogenic potential, how drugs can effectively modulate these networks and how resistance against targeted kinase inhibitors arises.

Most important Awards, Grants or Scientific Achievements

  • Spokesperson of the DFG Research Training Group 2424, CompCancer
  • Deputy spokesperson of the DFG collaborative research center 1588: Decoding and Targeting Mechanisms of Neuroblastoma Evolution

Selected References

  • Peidli, S.; Green, T. D.; Shen, C.; Gross, T.; Min, J.; Garda, S.; Taylor-King, J. P.; Marks, D. S.; Luna, A.; Blüthgen, N*. and Sander, C*.  scPerturb: Harmonized Single-Cell Perturbation Data, Nature Methods, in press.
  • Sell, T.; Klotz, C.; Fischer, M. M.; Astaburuaga-García, R.; Krug, S.; Drost, J.; Clevers, H.; Sers, C.; Morkel, M. and Blüthgen, N. (2023) "Oncogenic signaling is coupled to colorectal cancer cell differentiation state." Journal of Cell Biology, 222 (6).
  • Georg, P. *; Astaburuaga-Garcia, R. *; Bonaguro, L. *; Brumhard, S.; Michalick, L.; Lippert, L. J.; Kostevc, T.; Gäbel, C.; Schneider, M.; Streitz, M.; Demichev, V.; Gemünd, I.; Barone, M.; Tober-Lau, P.; Helbig, E. T.; Hillus, D.; Petrov, L.; Stein, J.; Dey, H-P.; Paclik, D.; Iwert, C.; Mülleder, M.; Aulakh, S. K.; Djudjaj, S.; Bülow, R. D.; Mei, H. E.; Schulz, A. R.; Thiel, A.; Hippenstiel, S.; Saliba, A-E.; Eils, R.; Lehmann, I.; Mall, M. A.; Stricker, S.; Röhmel, J.; Corman, V. M.; Beule, D.; Wyler, E.; Landthaler, M.; Obermayer, B.; von Stillfried, S.; Boor, P.; Demir, M.; Wesselmann, H.; Suttorp, N.; Uhrig, A.; Müller-Redetzky, H.; Nattermann, J.; Kuebler, W. M.; Meisel, C.; Ralser, M.; Schultze, J. L.; Aschenbrenner, A. C.; Thibeault, C.; Kurth, F.; Sander, L. E. *; Blüthgen, N. * and Sawitzki, B. *(2022) "Complement activation induces excessive T cell cytotoxicity in severe COVID-19." Cell, 185: 493-512.
  • Uhlitz, F.*; Bischoff, P.*; Peidli, S.*; Sieber, A.; Trinks, A.; Lüthen, M.; Obermayer, B.; Blanc, E.; Ruchiy, Y.; Sell, T.; Mamlouk, S.; Arsie, R.; Wei, T. T.; Klotz-Noack, K.; Schwarz, R. F.; Sawitzki, B.; Kamphues, C.; Beule, D.; Landthaler, M.; Sers, C.; Horst, D.; Blüthgen, N * and Morkel, M. * (2021) "Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer." EMBO Mol Med., 13: e14123.
  • Bischoff, P.; Trinks, A.; Wiederspahn, J.; Obermayer, B.; Pett, J.P.; Jurmeister, P.; Elsner, A.; Dziodzio, T.; Rückert, J.C.; Neudecker, J.; Falk, C.; Beule, D.; Sers, C.; Morkel, M.; Horst, D.; Klauschen, F. and Blüthgen, N. (2022) "The single-cell transcriptional landscape of lung carcinoid tumors." Int J Cancer, 150, 2022 , 2058-2071.
  • Brandt, R. *; Sell, T. *; Lüthen, M.; Uhlitz, F.; Klinger, B.; Riemer, P.; Giesecke-Thiel, C.; Schulze, S.; El-Shimy, I. A.; Kunkel, D.; Fauler, B.; Mielke, T.; Mages, N.; Herrmann, B. G; Sers, C.; Blüthgen, N. * and Morkel, M.* (2019) "Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium." Nature communications, 10 (1): 2919.